Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Braz. j. med. biol. res ; 40(12): 1661-1670, Dec. 2007. graf, tab
Article in English | LILACS | ID: lil-466745

ABSTRACT

Recombinant human thyroid-stimulating hormone (rhTSH) enhances 131I uptake, permitting a decrease in radiation for the treatment of multinodular goiter (MNG). Our objective was to evaluate the safety and efficacy of a single 0.1-mg dose of rhTSH, followed by 30 mCi 131I, in patients with MNG. Seventeen patients (15 females, 59.0 ± 13.1 years), who had never been submitted to 131I therapy, received a single 0.1-mg injection of rhTSH followed by 30 mCi 131I on the next day. Mean basal thyroid volume measured by computed tomography was 106.1 ± 64.4 mL. 131I 24-h uptake, TSH, free-T4, T3, thyroglobulin, anti-thyroid antibodies, and thyroid volume were evaluated at regular intervals of 12 months. Mean 131I 24-h uptake increased from 18.1 ± 9.7 to 49.6 ± 13.4 percent (P < 0.001), a median 2.6-fold increase (1.2 to 9.2). Peak hormonal levels were 10.86 ± 5.44 mU/L for TSH (a median 15.5-fold increase), 1.80 ± 0.48 ng/dL for free-T4, 204.61 ± 58.37 ng/dL for T3, and a median of 557.0 ng/mL for thyroglobulin. The adverse effects observed were hyperthyroidism (17.6 percent), painful thyroiditis (29.4 percent) and hypothyroidism (52.9 percent). Thyroid volume was reduced by 34.3 ± 14.3 percent after 6 months (P < 0.001) and by 46.0 ± 14.6 percent after 1 year (P < 0.001). Treatment of MNG with a single 0.1-mg dose of rhTSH, followed by a fixed amount of radioactivity of 131I, leads to an efficacious decrease in thyroid volume for the majority of the patients, with a moderate incidence of non-serious and readily treatable adverse effects.


Subject(s)
Female , Humans , Male , Middle Aged , Goiter, Nodular/radiotherapy , Iodine Radioisotopes/administration & dosage , Thyrotropin/administration & dosage , Combined Modality Therapy , Follow-Up Studies , Goiter, Nodular/drug therapy , Recombinant Proteins/administration & dosage , Treatment Outcome
2.
Braz. j. vet. res. anim. sci ; 35(5): 225-8, 1998. tab
Article in Portuguese | LILACS | ID: lil-266036

ABSTRACT

O trabalho foi desenvolvido utilizando-se 18 vacas leiteiras recém-paridas, da bacia leiteira de Curitiba (PR). Os animais eram semanalmente examinados por palpaçäo retal e aspectos de involuçäo uterina e atividade ovariana eram verificados. O início dos exames ocorreu em torno do 7º dia pós-parto (p.p.) e estendeu-se até o 49º. Concomitantemente foram colhidas dos animais amostras de leite da ordenha matinal a cada quatro dias, para posterior determinaçäo de progesterona, iniciando-se no 9º dia p.p. e estendendo-se até a 7º semana. As dosagens da progesterona (P4 subscrito) no leite magro foram realizadas pelo radioimunoensaio (RIA) em fase sólida. Os achados da pesquisa revelaram que a menor concentraçäo de P4 subscrito, detectada no leite foi de 0,01 ng/ml e a maior de 3,64 ng/ml, o 1º estro p.p. ocorreu no 28,5º dia e a detecçäo do 1º corpo lúteo (CL) teve lugar no 34,5º dia, o intervalo entre o estro e a 1º elevaçäo de P4 subscrito luteal foi em média de 5,5 dias, o intervalo parto/involuçäo uterina deu-se no 24,1º dia, o 1º corpo lúteo p.p. gerou período da dominância de P4 subscrito de apenas 11,5 dias e a concentraçäo média de P4 subscrito do 1º CL p.p. foi de 1,9 ng/ml, o 1º estro p.p. foi silencioso em 61,1 por cento dos casos e o percentual de anestro dos animais durante o período da pesquisa foi de 33,3 por cento


Subject(s)
Animals , Female , Cattle , Postpartum Period , Progesterone , Radioimmunoassay
SELECTION OF CITATIONS
SEARCH DETAIL